Literature DB >> 18398704

In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line.

Emmanuelle Brasnu1, Françoise Brignole-Baudouin, Luisa Riancho, Jean-Marc Guenoun, Jean-Michel Warnet, Christophe Baudouin.   

Abstract

PURPOSE: This study compared the toxicity profiles of three antiglaucoma prostaglandin F2alpha analogs, latanoprost, travoprost, and bimatoprost which contain benzalkonium chloride (BAK), with tafluprost, a new preservative-free prostaglandin analog.
METHODS: IOBA-NHC cells were exposed to BAK-containing prostanoid solutions, their respective BAK concentrations, and preservative-free tafluprost solution for 30 min. Membrane integrity, apoptosis, oxidative stress, and cells morphology were evaluated.
RESULTS: Preservative-free tafluprost resulted in significantly higher membrane integrity and lower pro-apoptotic and pro-oxidative effects than preservative-containing prostaglandin analog preparations.
CONCLUSIONS: These results suggest that tafluprost, a new preservative-free prostaglandin analog, has very low or no pro-apoptotic, pro-necrotic, or pro-oxidative effects in vitro compared to preservative-containing formulations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398704     DOI: 10.1080/02713680801971857

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  35 in total

1.  Short-term effect of topical brinzolamide-timolol fixed combination on ocular surface of glaucoma patients.

Authors:  Penpe Gul Firat; Emine Samdanci; Selim Doganay; Mufide Cavdar; Nurdan Sahin; Abuzer Gunduz
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

2.  A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study.

Authors:  Julia Tau; María Silvia Passerini; Melina Del Papa; Alejandro Aguilar; Alejandro Berra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-01-11       Impact factor: 3.117

3.  Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits.

Authors:  Abayomi B Ogundele; Guangming Li; Joel J Ellis
Journal:  Clin Ophthalmol       Date:  2010-02-18

4.  Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines.

Authors:  Masahiko Ayaki; Atsuo Iwasawa
Journal:  Clin Ophthalmol       Date:  2010-08-19

5.  Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.

Authors:  Dorota Pozarowska
Journal:  Clin Ophthalmol       Date:  2010-10-21

6.  Analysis of the effects of preservative-free tafluprost on the tear proteome.

Authors:  Sebastian Funke; Sabine Beck; Katrin Lorenz; Marion Kotterer; Dominik Wolters; Natarajan Perumal; Norbert Pfeiffer; Franz H Grus
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

7.  In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis).

Authors:  Christophe Baudouin; Alexandre Denoyer; Nicolas Desbenoit; Gregory Hamm; Alice Grise
Journal:  Trans Am Ophthalmol Soc       Date:  2012-12

8.  In vitro effects of preserved and unpreserved anti-allergic drugs on human corneal epithelial cells.

Authors:  Ana Guzman-Aranguez; Patricia Calvo; Inés Ropero; Jesús Pintor
Journal:  J Ocul Pharmacol Ther       Date:  2014-08-06       Impact factor: 2.671

9.  The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells.

Authors:  Tuomas Paimela; Tuomas Ryhänen; Anu Kauppinen; Liisa Marttila; Antero Salminen; Kai Kaarniranta
Journal:  Mol Vis       Date:  2012-05-06       Impact factor: 2.367

10.  Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay.

Authors:  Hong Liang; Christophe Baudouin; Marie-Odile Faure; Grégory Lambert; Françoise Brignole-Baudouin
Journal:  Mol Vis       Date:  2009-08-25       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.